Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bayer A G Ord (BAYZF)

Bayer A G Ord (BAYZF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 20.57
  • Price/Book 5.23
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.3100 +12.98%
on 03/04/26
47.5100 -1.77%
on 03/02/26
-2.6300 (-5.33%)
since 02/27/26
3-Month
41.3100 +12.98%
on 03/04/26
58.3276 -19.99%
on 02/17/26
+3.6550 (+8.50%)
since 12/31/25
52-Week
20.9900 +122.34%
on 04/09/25
58.3276 -19.99%
on 02/17/26
+22.6300 (+94.13%)
since 04/01/25

Most Recent Stories

More News
Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential

Nelson Ambrogio appointed to lead U.S. pharmaceuticals business, Bayer’s largest pharmaceutical growth market Appointment supports Bayer Pharmaceuticals’ strategy to renew top-line...

BAYRY : 11.6000 (+1.05%)
BAYZF : 46.6700 (+1.79%)
BAYN : 0.0100 (unch)
Bayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" Initiative

Bayer challenges industry to redefine canola innovation and reframe canola's future around real, lasting systems.

BAYRY : 11.6000 (+1.05%)
BAYZF : 46.6700 (+1.79%)
BAYN : 0.0100 (unch)
Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris

The social-first campaign humorously tackles extreme wellness trends while showcasing how Ludacris incorporates One A Day ® multivitamins...

BAYRY : 11.6000 (+1.05%)
BAYZF : 46.6700 (+1.79%)
BAYN : 0.0100 (unch)
Bayer Crop Science Launches 2026 Opportunity Scholarship Program

Bayer Crop Science Canada is excited to support the future of Canadian agriculture with its 2026 Bayer Crop Science Opportunity Scholarship. Through the scholarship, students entering post-secondary...

BAYRY : 11.6000 (+1.05%)
BAYZF : 46.6700 (+1.79%)
BAYN : 0.0100 (unch)
KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease

KERENDIA ® (finerenone) met its primary endpoint demonstrating a statistically significant improvement vs. placebo in the estimated glomerular filtration rate (eGFR) slope from baseline...

BAYRY : 11.6000 (+1.05%)
BAYZF : 46.6700 (+1.79%)
BAYN : 0.0100 (unch)
New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments

Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions Expanded Tesla compatibility captures...

BAYRY : 11.6000 (+1.05%)
BAYZF : 46.6700 (+1.79%)
BAYN : 0.0100 (unch)
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

  225 Ac-PSMA-Trillium (BAY 3563254) is an investigational targeted alpha therapy (TAT) being developed for patients with advanced metastatic castration-resistant prostate cancer (mCRPC)...

BAYRY : 11.6000 (+1.05%)
BAYZF : 46.6700 (+1.79%)
BAYN : 0.0100 (unch)
Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases

Final results for the key secondary endpoint of overall survival (OS) from the PEACE-3 trial will be presented by the European Organization for Research and Treatment of Cancer (EORTC) coalition as an...

BAYRY : 11.6000 (+1.05%)
BAYZF : 46.6700 (+1.79%)
BAYN : 0.0100 (unch)
Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA

Bayer files false advertising suit against J&J and Janssen Biotech Lawsuit seeks preliminary and permanent injunctions in addition to damages. This...

BAYRY : 11.6000 (+1.05%)
BAYZF : 46.6700 (+1.79%)
BAYN : 0.0100 (unch)
Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month

This February, the brand continues its See Your Risks initiative by challenging denial and bringing unseen heart health risk factors into view.

BAYRY : 11.6000 (+1.05%)
BAYZF : 46.6700 (+1.79%)
BAYN : 0.0100 (unch)

Business Summary

Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences, and crop sciences. Bayer's over-the-counter health-care product division is the third-largest in the world. HealthCare subgroup...

See More

Key Turning Points

3rd Resistance Point 46.6700
2nd Resistance Point 46.6700
1st Resistance Point 46.6700
Last Price 46.6700
1st Support Level 46.6700
2nd Support Level 46.6700
3rd Support Level 46.6700

See More

52-Week High 58.3276
Last Price 46.6700
Fibonacci 61.8% 44.0646
Fibonacci 50% 39.6588
Fibonacci 38.2% 35.2530
52-Week Low 20.9900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.